The Dorothy M. Davis Heart and Lung Research Institute, The Ohio State University Wexner Medical Center , Columbus, Ohio.
Department of Biomedical Engineering, College of Engineering, The Ohio State University , Columbus, Ohio.
Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H794-H801. doi: 10.1152/ajpheart.00197.2018. Epub 2018 Jun 22.
The mechanisms underlying Ca/calmodulin-dependent protein kinase II (CaMKII)-induced arrhythmias in ischemia-reperfusion (I/R) are not fully understood. We tested the hypothesis that CaMKII increases late Na current ( I) via phosphorylation of Na1.5 at Ser during I/R, thereby increasing arrhythmia susceptibility. To test our hypothesis, we studied isolated, Langendorff-perfused hearts from wild-type (WT) mice and mice expressing Na channel variants Na1.5-Ser571E (S571E) and Na1.5-Ser571A (S571A). WT hearts showed a significant increase in the levels of phosphorylated CaMKII and Na1.5 at Ser [p-Na1.5(S571)] after 15 min of global ischemia (just before the onset of reperfusion). Optical mapping experiments revealed an increase in action potential duration (APD) and APD dispersion without changes in conduction velocity during I/R in WT and S571E compared with S571A hearts. At the same time, WT and S571E hearts showed an increase in spontaneous arrhythmia events (e.g., premature ventricular contractions) and an increase in the inducibility of reentrant arrhythmias during reperfusion. Pretreatment of WT hearts with the Na channel blocker mexiletine (10 μM) normalized APD dispersion and reduced arrhythmia susceptibility during I/R. We conclude that CaMKII-dependent phosphorylation of Na1.5 is a crucial driver for increased I arrhythmia triggers, and substrate during I/R. Selective targeting of this CaMKII-dependent pathway may have therapeutic potential for reducing arrhythmias in the setting of I/R. NEW & NOTEWORTHY Ca/calmodulin-dependent protein kinase II (CaMKII) phosphorylation of Na1.5 at Ser leads to a prolongation of action potential duration (APD), increased APD dispersion, and increased arrhythmia susceptibility after ischemia-reperfusion in isolated mouse hearts. Genetic ablation of the CaMKII-dependent phosphorylation site Ser on Na1.5 or low-dose mexiletine (to inhibit late Na current) reduced APD dispersion, arrhythmia triggers, and ventricular tachycardia inducibility.
钙/钙调蛋白依赖性蛋白激酶 II(CaMKII)诱导缺血再灌注(I/R)心律失常的机制尚不完全清楚。我们检验了这样一个假设,即在 I/R 期间,CaMKII 通过磷酸化 Na1.5 上的丝氨酸(Ser)来增加晚期钠电流(I),从而增加心律失常易感性。为了验证我们的假设,我们研究了来自野生型(WT)小鼠和表达 Na 通道变体 Na1.5-Ser571E(S571E)和 Na1.5-Ser571A(S571A)的 Langendorff 灌注心脏的分离心脏。在 15 分钟的全缺血(就在再灌注开始之前)后,WT 心脏中磷酸化的 CaMKII 和 Na1.5 上的丝氨酸 [p-Na1.5(S571)] 的水平显著增加。光学映射实验显示,与 S571A 心脏相比,在 I/R 期间,WT 和 S571E 心脏的动作电位持续时间(APD)延长和 APD 离散度增加,而传导速度没有变化。与此同时,WT 和 S571E 心脏在再灌注期间显示自发性心律失常事件(例如,室性早搏)增加,以及折返性心律失常的诱导性增加。WT 心脏用 Na 通道阻滞剂美西律(10 μM)预处理可使 I/R 期间 APD 离散度正常化并降低心律失常易感性。我们得出的结论是,CaMKII 依赖性 Na1.5 磷酸化是 I/R 期间增加 I 心律失常触发和底物的关键驱动因素。针对这种 CaMKII 依赖性途径的选择性靶向可能具有减少 I/R 中心律失常的治疗潜力。
新的和值得注意的是,在分离的小鼠心脏中,Ca/calmodulin 依赖性蛋白激酶 II(CaMKII)在 Ser 上对 Na1.5 的磷酸化导致动作电位持续时间(APD)延长,APD 离散度增加,缺血再灌注后心律失常易感性增加。Na1.5 上 CaMKII 依赖性磷酸化位点 Ser 的基因缺失或低剂量美西律(抑制晚期钠电流)减少了 APD 离散度、心律失常触发和室性心动过速的诱导性。